Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Active Biotech on private placement
Mandate

Vinge has advised Active Biotech on private placement

February 03, 2011

Active Biotech AB (publ) (NASDAQ OMX Stockholm) has carried out a private placement of new shares of SEK 375 million directed towards international institutional investors and qualified investors in Sweden.

Vinge acted for Active Biotech. Vinge’s team consisted of Erik Sjöman and Christian Lindhé.

Related

Vinge has advised Sluta Gräva in connection with its acquisition of Stavrex

 Vinge has advised Sluta Gräv, a portfolio company of Sobro, in connection with the acquisition of Stavrex. Together, the companies form the Nordic region’s leading supplier of ground screws, with the market’s broadest offering.
February 18, 2026

Vinge advises Stendörren in connection with issuance of subsequent green bonds

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of subsequent senior unsecured green bonds in an amount of SEK 300 million (within a framework of SEK 800 million).
February 18, 2026

Vinge advises DNB Carnegie in connection with a EUR 130 million bond issue to finance Incore Invest’s acquisition of CoreOrchestration

 Vinge has advised DNB Carnegie Investment Bank AB (publ), in its capacity as sole bookrunner, in connection with an issue of senior secured bonds of EUR 130 million under a framework of EUR 200 million.
February 16, 2026